These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18177593)

  • 1. A novel means to demonstrate early efficacy of a product in systemic lupus erythematosus.
    Strand V
    Curr Rheumatol Rep; 2007 Dec; 9(6):427-30. PubMed ID: 18177593
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials in systemic lupus erythematosus.
    Buyon JP
    Curr Rheumatol Rep; 2000 Feb; 2(1):11-12. PubMed ID: 11123033
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel therapies in the treatment of systemic lupus erythematosus.
    Dequet CR; Wallace DJ
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1045-53. PubMed ID: 11892912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dehydroepiandrosterone in the treatment of systemic lupus erythematosus.
    van Vollenhoven RF
    Rheumatology (Oxford); 2000 Aug; 39(8):929-30. PubMed ID: 10952759
    [No Abstract]   [Full Text] [Related]  

  • 5. Disease activity assessment in SLE: do we have the right instruments?
    Petri M
    Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii61-4. PubMed ID: 17934099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic Review and Meta-analysis.
    Shamliyan TA; Dospinescu P
    Clin Ther; 2017 Jul; 39(7):1479-1506.e45. PubMed ID: 28673504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.
    Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
    Ann Rheum Dis; 2019 Jul; 78(7):1006-1007. PubMed ID: 30610063
    [No Abstract]   [Full Text] [Related]  

  • 8. Prasterone and bone mineral density in women with systemic lupus erythematosus.
    Alexander T; Friel PN; Wright JV
    J Rheumatol; 2005 Dec; 32(12):2497; author reply 2497-8. PubMed ID: 16331796
    [No Abstract]   [Full Text] [Related]  

  • 9. Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial.
    Lai JS; Beaumont JL; Ogale S; Brunetta P; Cella D
    J Rheumatol; 2011 Apr; 38(4):672-9. PubMed ID: 21239746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of systemic lupus erythematosus.
    Mosca M; Ruiz-Irastorza G; Khamashta MA; Hughes GR
    Int Immunopharmacol; 2001 Jun; 1(6):1065-75. PubMed ID: 11407302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic therapies in systemic lupus erythematosus.
    Bernal CB; Zamora LD; Navarra SV
    Int J Rheum Dis; 2015 Feb; 18(2):146-53. PubMed ID: 25884458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.
    Barry NN; McGuire JL; van Vollenhoven RF
    J Rheumatol; 1998 Dec; 25(12):2352-6. PubMed ID: 9858429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study of T lymphocyte subpopulations in patients with lupus erythematosus using monoclonal antibodies during immunocorrective therapy].
    Berenbeĭn BA; Kagramanov GV; Slavina EG
    Vestn Dermatol Venerol; 1987; (3):10-3. PubMed ID: 3300088
    [No Abstract]   [Full Text] [Related]  

  • 14. Dehydroepiandrosterone in systemic lupus erythematosus.
    van Vollenhoven RF
    Rheum Dis Clin North Am; 2000 May; 26(2):349-62. PubMed ID: 10768216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through?
    Dall'Era M; Wofsy D
    Nat Rev Rheumatol; 2010 Mar; 6(3):124-5. PubMed ID: 20197774
    [No Abstract]   [Full Text] [Related]  

  • 16. Systemic Lupus Erythematosus and Critical Illness.
    Gasser EK; Schell-Chaple HM
    AACN Adv Crit Care; 2020 Sep; 31(3):296-307. PubMed ID: 32866257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasterone.
    Kocis P
    Am J Health Syst Pharm; 2006 Nov; 63(22):2201-10. PubMed ID: 17090740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dehydroepiandrosterone for systemic lupus erythematosus.
    Crosbie D; Black C; McIntyre L; Royle PL; Thomas S
    Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD005114. PubMed ID: 17943841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
    Petri MA; Mease PJ; Merrill JT; Lahita RG; Iannini MJ; Yocum DE; Ginzler EM; Katz RS; Gluck OS; Genovese MC; Van Vollenhoven R; Kalunian KC; Manzi S; Greenwald MW; Buyon JP; Olsen NJ; Schiff MH; Kavanaugh AF; Caldwell JR; Ramsey-Goldman R; St Clair EW; Goldman AL; Egan RM; Polisson RP; Moder KG; Rothfield NF; Spencer RT; Hobbs K; Fessler BJ; Calabrese LH; Moreland LW; Cohen SB; Quarles BJ; Strand V; Gurwith M; Schwartz KE
    Arthritis Rheum; 2004 Sep; 50(9):2858-68. PubMed ID: 15452837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.